Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
Phase 3
Completed
- Conditions
- Postmenopausal Women With Osteoporosis
- Interventions
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 4093
- Registration Number
- NCT01631214
- Locations
- 🇬🇧
Research Site, Warwick, United Kingdom
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis
Phase 1
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: AMG 811 or Placebo
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2013-03-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 9
- Registration Number
- NCT01510951
- Locations
- 🇳🇿
Research Site, Grafton, Auckland, New Zealand
AMG 595 First-in-Human in Recurrent Gliomas
Phase 1
Completed
- Conditions
- Glioblastoma MultiformeAnaplastic AstrocytomasAdvanced Malignant Glioma
- Interventions
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT01475006
- Locations
- 🇦🇺
Research Site, Parkville, Victoria, Australia
AMG 151 Amgen Protocol Number 20100761
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2014-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 236
- Registration Number
- NCT01464437
- Locations
- 🇵🇷
Research Site, San Juan, Puerto Rico
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Phase 2
Completed
- Conditions
- CarcinoidSarcomaSolid TumorsLymphomaColorectal CancerMetastatic CancerAdvanced Solid TumorsLocally AdvancedNon-Small Cell Lung Cancer
- Interventions
- Biological: GanitumabBiological: ConatumumabDrug: Modified FOLFOX6Biological: Bevacizumab
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 12
- Registration Number
- NCT01327612
- Locations
- 🇪🇸
Research Site, Barcelona, Cataluña, Spain
Pediatric Chronic Kidney Disease Safety and Efficacy
Phase 3
Terminated
- Conditions
- Chronic Kidney DiseaseKidney DiseaseSecondary HyperparathyroidismHyperparathyroidism, SecondaryHyperparathyroidism
- Interventions
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 43
- Registration Number
- NCT01277510
- Locations
- 🇪🇸
Research Site, Madrid, Spain
PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Phase 3
Completed
- Conditions
- Psoriatic Arthritis
- Interventions
- First Posted Date
- 2010-10-01
- Last Posted Date
- 2020-05-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 505
- Registration Number
- NCT01212770
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Desert Medical Advances, Palm Desert, California, United States
🇺🇸Rockford Orthopedic Associates, LLC, Rockford, Illinois, United States
Long-term Safety Study of Brodalumab in Adults With Crohn's Disease
Phase 2
Terminated
- Conditions
- Crohn's Disease
- Interventions
- Biological: Brodalumab
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 67
- Registration Number
- NCT01199302
- Locations
- 🇪🇸
Research Site, Pontevedra, Galicia, Spain
Study To Assess FRacTure Healing With SclerosTin Antibody - Hip
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 332
- Registration Number
- NCT01081678
- Locations
- 🇬🇧
Research Site, Norwich, United Kingdom
Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy
- First Posted Date
- 2009-06-12
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 870
- Registration Number
- NCT00919711
© Copyright 2025. All Rights Reserved by MedPath